Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18- and ≤77-years-old~* Type 2 diabetes~* Taking metformin immediate release (IR) or XR ≥1500 mg for at least 8 weeks as monotherapy~* Glycosylated hemoglobin (A1C) ≥7% and ≤10%~* Body mass index (BMI) ≤40 kg/m2~Exclusion Criteria:~* Women of childbearing potential unable or unwilling to use acceptable birth control~* Women who are pregnant or breastfeeding~* Significant cardiovascular history~* Active liver disease~* Renal impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin 5 mg + Metformin (Type: EXPERIMENTAL): None
- Placebo + Metformin (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).